A. Fiorentini,F. Regispani, S. Beraldo, V.M.S. Ferrari, A.C. Omboni, L.S. Volonteri, M.C. Mauri - Vol. 10, June 2004, Issue 2
Testo Immagini Bibliografia Summary Indice
Utilizzo dei farmaci antipsicotici nel
Servizio Psichiatrico di Diagnosi e Cura (SPDC) dell’Ospedale Maggiore di
Milano
negli anni 1989, 1999 e 2002
Antipsychotic drug use at the inpatient unit of the Milan Psychiatric
Clinic (Ospedale Maggiore) during 1989, 1999 and 2002
1 Glick ID, Murray SR, Vasudevan P, Marder SR, Hu RJ. Treatment with atypical antipsychotics: new indications and new populations. J Psychiatr Res 2001;56:187-91.
2 American Psychiatric Association. Practice guideline for the treatment of patient with schizophrenia. Am J Psychiatry 1997;154(Suppl 4):1-63.
3 Moller HJ. Novel antipsychotics and negative symptoms. Int Clin Psychopharmacol 1998;13(Suppl 3):S43-7.
4 Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analiysis of randomised controlled trials. Schizophr Res 1999;35:51-68.
5 Leslie DL, Roseneheck RA. From conventional to atypical antipsychotics and back: dynamic process in the diffusion of new medications. Am J Psychiatry 2002;159:1534-40.
6 Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br Med J 2000;321:1371-6.
7 Lambert TJR, Castle DJ. Pharmacological approaches to the management of schizophrenia. Schizophrenia 2003;178:s57-s61.
8 Lieberman JA. Atypical antipsychotic drugs as first-line treatment of schizophrenia: a rationale and hypothesis. J Clin Psychiatry 1996;57(Suppl 11):68-71.
9 Allison DB, Mentore JL, Heo M, Weiden P, Cappellieri J, Chandler LP. Weight gain associated with conventional and newer antipsychotics: a meta-analysis. Eur Neuropsychopharmacol 1998;8(Suppl 2):S 216.
10 Wirshing DA, Spellberg BJ, Erhart SM. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;44:778-83.
11 Lieberman JA, Golden R, Stroup S, McEvoy J. Drugs of the psychopharmacological revolution in clinical psychiatry. Psychiatr Serv 2000;51:1254-8.
12 Hugenholltz WKG, Stolker JJ, Heerdink ER, Nolen WA, Leuflkens GM. Short-acting parenteral antipsychotics drive choice for classical versus atypical agents. Eur J Clin Pharmacol 2003.
13 Hudson TJ, Sullivan G, Feng W, Owen RR, Thrush CR. Economic evaluations of novel antipsychotic medications: a literature review. Schizophr Res 2003;60:199-218.
14 McCombs JS, Nichol MB, Johnstone BM, Shi J, Smith R. Antipsychotic drug use patterns and the cost of treating schizophrenia. Psychiatr Serv 2000;51:525-7.
15 Kane JA, Carpenter D, Docherty JP. The Expert Consensus Guideline Series: optimizing pharmachologic treatment of psychotic disorders. J Clin Psychiaty 2003;64(Suppl 12):1-100.
16 McEvoy JP, Scheifler PL, Frances A. The expert Consensus Guideline Series: Treatment of schizophrenia1999. J Clin Psychiaty 1999;60(Suppl 11):3-80.
17 Ereshefsky L. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychiaty 1999;60(Suppl 10):20-30.
18 Buckley PF, Miller DD, Singer B, Donenwirth K. What’s new with the new antipsychotics? Presented at the annual Meeting of the American College of Neuropsychopharmacology; 1999 December; Acapulco, Mexico.
19 Martin CB, Miller LS, Kotzan JA. Antipsychotic prescription use and costs for persons with schizophrenia in the 1990s: current trends and five year time series forecast. Schizophr Res 2001;47:281-92.
20 Rossi I, Guidi L. Valutazione dei costi di trattamento dei disturbi psicotici con olanzapina, risperidone e neurolettici tipici in un dsm italiano. Ital J Psychopathol 2002;8(Suppl):s13-s16.
21 Keks NA, Altson K, Hope J, Krapivensky N, Culhane C, Tanaghow A, et al. Use of antipsychotics and adjiunctive medications by an inner urban community psychiatryc service. Aust NZ J Psychiatry 1999;33:896-901.
22 Fourrier A, Gasquet I, Allicar MP. Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists. J Clin Pharmacol 1999;49:80-6.
23 Rittmannsberger H, Meise U, Schauflinger K. Polypharmacy in psychiatric treatment: patterns of psychotropic drug use in Austrian psychiatric clinics. Eur Psychiatry 1999;14:33-40.
24 Stahl SM. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. J Clin Psychiatry 1999;60(Suppl 10):31-9.
25 Meltzer HY, Kostaoglu AE. Combing antipsychotics: is there evidence for efficacy? Psychiatr Times 2000;17:25-34.
26 Lachaux B, Sontag H, Casadebaig F, Philippe A, Rouillon F, Clery-Melin P, et al. Pharmacoepidemiological study on antipsychotic drug prescription in French Psychiatry: patient characteristics, antipsychotic treatment, and care management for schizophrenia. Encephale 2002;28:129-38.
27 Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002;106:323-30.
28 Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N. Combination antipsychotic therapy in clinical practice. Psychiatr Serv 2003;54:55-9.
29 Centorrino F, Eakin M, Bahk WM, Kellehr JP, Goren J, Salvatore P et al. Inpatient antipsychotic drug use in 1998, 1993, and 1989. Am J Psychiatry 2002:1932-5.
30 Stahl SM. Antipsychotic polypharmacy: therapeutic option or dirty little secret? J Clin Psychiatry 1999;60:425-6.